Wall Street Zen upgraded shares of Tenaya Therapeutics (NASDAQ:TNYA – Free Report) from a strong sell rating to a sell rating in a research report sent to investors on Sunday morning,Wall Street Zen reports.
Separately, Weiss Ratings raised shares of Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Tenaya Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $4.00.
Check Out Our Latest Research Report on TNYA
Tenaya Therapeutics Stock Performance
Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.13). The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $10.00 million. As a group, equities research analysts predict that Tenaya Therapeutics will post -0.38 EPS for the current fiscal year.
Institutional Trading of Tenaya Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the company. Woodline Partners LP increased its position in Tenaya Therapeutics by 30,563.2% during the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company’s stock valued at $3,373,000 after purchasing an additional 5,896,873 shares during the period. Empery Asset Management LP purchased a new stake in shares of Tenaya Therapeutics in the 4th quarter worth approximately $3,852,000. Anson Funds Management LP purchased a new stake in shares of Tenaya Therapeutics in the 4th quarter worth approximately $2,955,000. BlackRock Inc. bought a new position in shares of Tenaya Therapeutics during the second quarter valued at approximately $2,963,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Tenaya Therapeutics during the fourth quarter valued at approximately $2,846,000. 90.54% of the stock is currently owned by institutional investors.
Tenaya Therapeutics Company Profile
Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.
Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.
Read More
- Five stocks we like better than Tenaya Therapeutics
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
